|
End-of-day quote
Taipei Exchange
08/10/2026
|
5-day change | 1st Jan Change | ||
| 175.00 TWD | +1.16% |
|
-3.58% | +340.81% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 145B 4.54B 4.05B 3.77B 3.43B 6.48B 439B 6.51B 45.39B 17.79B 224B 17.05B 16.67B 719B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 129B 4.03B 3.6B 3.35B 3.05B 5.75B 390B 5.78B 40.3B 15.79B 199B 15.14B 14.81B 638B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.16% | ||
| 1 week | -3.58% | ||
| Current month | -8.14% | ||
| 1 month | +3.86% | ||
| 3 months | +185.95% | ||
| 6 months | +347.00% | ||
| Current year | +340.81% |
| 1 week | 169 |  | 184 |
| 1 month | 155 | | 207 |
| Current year | 33.1 | | 207 |
| 1 year | 20.4 | | 207 |
| 3 years | 7 | | 207 |
| 5 years | 7 | | 207 |
| 10 years | 2.7 | | 207 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 31/05/2016 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 24/07/2022 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 12/10/2016 |
Cheng Chi Wang
BRD | Director/Board Member | - | 26/06/2024 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 26/09/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.16% | -3.58% | +693.65% | +1,527.91% | 4.54B | |
| +0.83% | +3.19% | +41.49% | +103.56% | 1,051B | |
| +1.93% | +2.11% | +37.08% | +65.09% | 630B | |
| +1.49% | +5.19% | +19.94% | +85.69% | 489B | |
| +2.26% | +0.90% | +69.32% | +40.53% | 359B | |
| +1.45% | +3.50% | +23.29% | +41.62% | 344B | |
| +1.17% | +2.37% | +13.47% | +33.64% | 272B | |
| +0.89% | +1.08% | -6.13% | +9.29% | 246B | |
| +1.82% | +2.94% | +42.99% | +52.95% | 224B | |
| +2.77% | +4.44% | +29.01% | +98.99% | 187B | |
| Average | +1.58% | +1.92% | +96.41% | +205.93% | 380.82B | |
| Weighted average by Cap. | +1.47% | +2.44% | +34.14% | +70.75% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -23.28M -20.79M -19.34M -17.6M -33.22M -2.25B -33.37M -233M -91.22M -1.15B -87.44M -85.52M -3.69B | -1.36B -42.64M -38.08M -35.42M -32.22M -60.83M -4.13B -61.1M -426M -167M -2.1B -160M -157M -6.75B |
| Net Debt | -5.17B -162M -145M -134M -122M -231M -15.67B -232M -1.62B -634M -7.99B -608M -595M -25.63B | -16.27B -509M -455M -423M -385M -726M -49.26B -729M -5.09B -1.99B -25.11B -1.91B -1.87B -80.59B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/10/26 | NT$175.00 | +1.16% | 2,884,939 |
| 07/10/26 | NT$173.00 | -3.89% | 4,844,408 |
| 06/10/26 | NT$180.00 | +4.96% | 4,859,908 |
| 05/10/26 | NT$171.50 | -5.51% | 11,835,303 |
| 02/10/26 | NT$181.50 | -3.46% | 9,459,167 |
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
